Bantingmed offers a digital program for type 2 diabetes remission, providing personalized treatment plans and medication based on global research. The platform aims to improve metabolic health and reduce diabetes risk through accessible, data-driven interventions.
Funding
$6.4K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Individuals diagnosed with type 2 diabetes face challenges in achieving remission due to the complexity of current management protocols and the lack of personalized, accessible interventions. This often leads to progressive disease and associated comorbidities.
Solution
Bantingmed provides a digital diabetes remission program that leverages personalized treatment plans and medication to address type 2 diabetes. The platform synthesizes insights from extensive global research to create tailored interventions for each user. By focusing on a data-driven approach, Bantingmed aims to facilitate significant reductions in diabetes risk and improve metabolic health outcomes. The program is designed for broad accessibility, offering a structured pathway for individuals seeking to reverse their diabetic status.
Target Audience
Individuals diagnosed with type 2 diabetes seeking a structured, personalized program for disease remission and improved metabolic health.
Features
- Personalized treatment protocols informed by global diabetes research.
- Tailored medication regimens to support metabolic health.
- Digital platform for program delivery and progress tracking.
- Focus on risk reduction and potential diabetes remission.
- Accessible program design for remote users.